HRP20191137T1 - Formulacije otopina konstruiranih anti-il-23p19 antitijela - Google Patents
Formulacije otopina konstruiranih anti-il-23p19 antitijela Download PDFInfo
- Publication number
- HRP20191137T1 HRP20191137T1 HRP20191137TT HRP20191137T HRP20191137T1 HR P20191137 T1 HRP20191137 T1 HR P20191137T1 HR P20191137T T HRP20191137T T HR P20191137TT HR P20191137 T HRP20191137 T HR P20191137T HR P20191137 T1 HRP20191137 T1 HR P20191137T1
- Authority
- HR
- Croatia
- Prior art keywords
- formulation
- antibody hum13b8
- hum13b8
- antibody
- use according
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title claims 13
- 239000000203 mixture Substances 0.000 title claims 13
- 239000000243 solution Substances 0.000 claims 6
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (10)
1. Formulacija otopina anti-IL-23p19 antitijela hum13B8-b, koja sadrži:
a) najmanje 50 mg/ml anti-IL-23p19 antitijela hum13B8-b;
b) 10 mM histidinskog pufera, pH 6,0;
c) 0.05% polisorbata 80; i
d) 7% saharoze,
pri čemu navedeno antitijelo hum13B8-b sadrži:
i) polipeptid lakog lanca koji sadrži sekvencu SEQ ID NO: 2; i
ii) polipeptid teškog lanca koji sadrži sekvencu SEQ ID NO: 1.
2. Formulacija otopina prema patentnom zahtjevu 1 koja sadrži najmanje 80 mg/ml anti-IL-23p19 antitijela hum13B8-b.
3. Formulacija otopina prema patentnom zahtjevu 2 koja sadrži najmanje 100 mg/ml anti-IL-23p19 antitijela hum13B8-b.
4. Formulacija otopina prema patentnom zahtjevu 1 koja sadrži 80 - 120 mg/ml anti-IL-23p19 antitijela hum13B8-b.
5. Formulacija otopina prema patentnom zahtjevu 4 koja sadrži 100 mg/ml anti-IL-23p19 antitijela hum13B8-b.
6. Formulacija otopina prema bilo kojem od patentnih zahtjeva 1 - 5 za uporabu u liječenju autoimune bolesti, inflamatorne bolesti ili proliferativnog poremećaja.
7. Formulacija za uporabu prema patentnom zahtjevu 6 naznačena time što se formulacija primjenjuje potkožno.
8. Formulacija za uporabu prema patentnom zahtjevu 7 naznačena time što se potkožna primjena obavlja putem injekcije upotrebom šprica, auto-injektora, injekcijske olovke ili injekcijskog uređaja bez igle.
9. Formulacija za uporabu prema patentnom zahtjevu 6 naznačena time što se formulacija primjenjuje u kvartalnim intervalima.
10. Formulacija za uporabu prema patentnom zahtjevu 6 naznačena time što je inflamatorna bolest psorijaza.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737035P | 2012-12-13 | 2012-12-13 | |
| PCT/US2013/073825 WO2014093203A1 (en) | 2012-12-13 | 2013-12-09 | SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES |
| EP13863590.9A EP2931313B1 (en) | 2012-12-13 | 2013-12-09 | Solution formulations of engineered anti-il-23p19 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191137T1 true HRP20191137T1 (hr) | 2019-09-20 |
Family
ID=50934859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191137TT HRP20191137T1 (hr) | 2012-12-13 | 2019-06-21 | Formulacije otopina konstruiranih anti-il-23p19 antitijela |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20150329632A1 (hr) |
| EP (1) | EP2931313B1 (hr) |
| JP (1) | JP6266012B2 (hr) |
| KR (1) | KR102004585B1 (hr) |
| CN (1) | CN104870016B (hr) |
| AU (1) | AU2013359767B2 (hr) |
| BR (1) | BR112015013540B1 (hr) |
| CA (1) | CA2894869C (hr) |
| CL (1) | CL2015001608A1 (hr) |
| CY (1) | CY1121895T1 (hr) |
| DK (1) | DK2931313T3 (hr) |
| EA (1) | EA034616B1 (hr) |
| ES (1) | ES2732861T3 (hr) |
| HK (1) | HK1215194A1 (hr) |
| HR (1) | HRP20191137T1 (hr) |
| HU (1) | HUE045668T2 (hr) |
| IL (3) | IL278295B2 (hr) |
| LT (1) | LT2931313T (hr) |
| MX (1) | MX357936B (hr) |
| MY (1) | MY187921A (hr) |
| NZ (1) | NZ708443A (hr) |
| PE (1) | PE20151524A1 (hr) |
| PH (1) | PH12015501296B1 (hr) |
| PL (1) | PL2931313T3 (hr) |
| PT (1) | PT2931313T (hr) |
| RS (1) | RS59057B1 (hr) |
| SI (1) | SI2931313T1 (hr) |
| TR (1) | TR201909584T4 (hr) |
| UA (1) | UA117466C2 (hr) |
| WO (1) | WO2014093203A1 (hr) |
| ZA (1) | ZA201504408B (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI761959B (zh) * | 2014-11-07 | 2022-04-21 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| TWI775827B (zh) * | 2017-03-31 | 2022-09-01 | 日商明治製菓藥業股份有限公司 | 水性製劑及裝入注射器之水性製劑以及抗體蛋白去凝集劑及抗體蛋白去凝集方法 |
| KR20200129125A (ko) * | 2018-03-05 | 2020-11-17 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 크론병을 치료하는 방법 |
| AU2019384160A1 (en) * | 2018-11-21 | 2021-05-27 | Regeneron Pharmaceuticals, Inc. | High concentration protein formulation |
| CA3129901A1 (en) | 2019-02-18 | 2020-08-27 | Eli Lilly And Company | Therapeutic antibody formulation |
| EP3928101A1 (en) * | 2019-02-20 | 2021-12-29 | Amgen Inc. | Methods of determining protein stability |
| JP2022534020A (ja) | 2019-05-23 | 2022-07-27 | ヤンセン バイオテツク，インコーポレーテツド | Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 |
| TW202123965A (zh) * | 2019-09-09 | 2021-07-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| WO2021126435A1 (en) * | 2019-12-20 | 2021-06-24 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
| AU2021272212A1 (en) * | 2020-05-13 | 2022-12-08 | Innovent Biologics (Suzhou) Co., Ltd. | Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60041393D1 (de) | 1999-03-11 | 2009-03-05 | Schering Corp | Cytokine aus säugetieren, verwandte reagenzien und verfahren |
| CN100529076C (zh) | 1999-09-09 | 2009-08-19 | 先灵公司 | 哺乳动物细胞因子、相关试剂和方法 |
| CA2454587C (en) | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| WO2003039485A2 (en) * | 2001-11-08 | 2003-05-15 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| WO2004071517A2 (en) | 2003-02-06 | 2004-08-26 | Schering Corporation | Uses of il-23 related reagents |
| SI3417875T1 (sl) | 2003-02-10 | 2021-01-29 | Biogen Ma Inc. | Formulacija imunoglobulina in metode za njegovo pripravo |
| AU2004219625B9 (en) | 2003-03-10 | 2010-12-23 | Merck Sharp & Dohme Corp. | Uses of IL-23 agonists and antagonists; related reagents |
| EP3178492A1 (en) * | 2003-04-04 | 2017-06-14 | Genentech, Inc. | High concentration antibody and protein formulations |
| ATE533502T1 (de) | 2004-02-17 | 2011-12-15 | Schering Corp | Verfahren zur modulation der il-23-aktivität; relevante reagenzien |
| CA2562771C (en) | 2004-04-12 | 2013-04-09 | Medimmune, Inc. | Anti-il-9 antibody formulations and uses thereof |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| PT2452694T (pt) | 2005-06-30 | 2019-02-21 | Janssen Biotech Inc | Anticorpos anti-il-23, composições, métodos e utilizações |
| DK1937721T3 (da) | 2005-08-25 | 2010-10-18 | Lilly Co Eli | Anti-IL-23 antistoffer |
| PL1931710T3 (pl) | 2005-08-31 | 2017-06-30 | Merck Sharp & Dohme Corp. | Przeciwciała anty-il-23 skonstruowane techniką inżynierii genetycznej |
| PT1971366E (pt) | 2005-12-29 | 2014-11-06 | Janssen Biotech Inc | Anticorpos humanos anti-il-23, composições, métodos e usos |
| CA2655372A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| US7705132B2 (en) | 2006-10-20 | 2010-04-27 | Amgen Inc. | Stable polypeptide formulations |
| MX2009007406A (es) | 2007-01-09 | 2010-01-25 | Wyeth Corp | Formulaciones de anticuerpo anti-il-13 y usos de las mismas. |
| TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Ｉｌ-２３拮抗劑於治療感染之用途 |
| SI2059534T1 (sl) * | 2007-02-23 | 2012-08-31 | Schering Corp | Umetno proizvedena anti-il-23p19 antitelesa |
| CN101663320A (zh) | 2007-02-23 | 2010-03-03 | 先灵公司 | 工程改造的抗IL-23p19抗体 |
| US20090208492A1 (en) | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| EP2205276A4 (en) | 2007-09-28 | 2012-08-15 | Janssen Biotech Inc | ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| SI2234600T1 (sl) | 2007-12-21 | 2014-12-31 | F. Hoffmann-La Roche Ag | Farmacevtska oblika protitelesa |
| EP3002299A1 (en) * | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| CN102202655B (zh) * | 2008-08-27 | 2013-06-19 | 默沙东公司 | 基因工程抗IL-23p19抗体的冻干制剂 |
| EP2331090B1 (en) * | 2008-09-19 | 2018-01-03 | Pfizer Inc. | Stable liquid antibody formulation |
| AU2009319856A1 (en) * | 2008-11-28 | 2010-06-03 | Abbvie Inc. | Stable antibody compositions and methods for stabilizing same |
| MX2012007676A (es) * | 2009-12-29 | 2012-08-03 | Hoffmann La Roche | Nueva formulacion de anticuerpo. |
| US9220776B2 (en) | 2011-03-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| NZ629261A (en) * | 2012-03-07 | 2017-08-25 | Cadila Healthcare Ltd | Pharmaceutical formulations of tnf-alpha antibodies |
-
2013
- 2013-09-12 UA UAA201506824A patent/UA117466C2/uk unknown
- 2013-12-09 MX MX2015007213A patent/MX357936B/es active IP Right Grant
- 2013-12-09 KR KR1020157018314A patent/KR102004585B1/ko active IP Right Grant
- 2013-12-09 NZ NZ708443A patent/NZ708443A/en unknown
- 2013-12-09 RS RS20190822A patent/RS59057B1/sr unknown
- 2013-12-09 HU HUE13863590A patent/HUE045668T2/hu unknown
- 2013-12-09 CA CA2894869A patent/CA2894869C/en active Active
- 2013-12-09 ES ES13863590T patent/ES2732861T3/es active Active
- 2013-12-09 WO PCT/US2013/073825 patent/WO2014093203A1/en active Application Filing
- 2013-12-09 EP EP13863590.9A patent/EP2931313B1/en active Active
- 2013-12-09 IL IL278295A patent/IL278295B2/en unknown
- 2013-12-09 BR BR112015013540-4A patent/BR112015013540B1/pt active IP Right Grant
- 2013-12-09 IL IL307581A patent/IL307581A/en unknown
- 2013-12-09 DK DK13863590.9T patent/DK2931313T3/da active
- 2013-12-09 PL PL13863590T patent/PL2931313T3/pl unknown
- 2013-12-09 AU AU2013359767A patent/AU2013359767B2/en active Active
- 2013-12-09 US US14/651,946 patent/US20150329632A1/en active Pending
- 2013-12-09 TR TR2019/09584T patent/TR201909584T4/tr unknown
- 2013-12-09 JP JP2015547448A patent/JP6266012B2/ja active Active
- 2013-12-09 PE PE2015000925A patent/PE20151524A1/es active IP Right Grant
- 2013-12-09 PT PT13863590T patent/PT2931313T/pt unknown
- 2013-12-09 CN CN201380065606.7A patent/CN104870016B/zh active Active
- 2013-12-09 EA EA201591133A patent/EA034616B1/ru unknown
- 2013-12-09 MY MYPI2015701965A patent/MY187921A/en unknown
- 2013-12-09 LT LTEP13863590.9T patent/LT2931313T/lt unknown
- 2013-12-09 SI SI201331504T patent/SI2931313T1/sl unknown
-
2015
- 2015-06-02 IL IL239150A patent/IL239150B/en active IP Right Grant
- 2015-06-08 PH PH12015501296A patent/PH12015501296B1/en unknown
- 2015-06-10 CL CL2015001608A patent/CL2015001608A1/es unknown
- 2015-06-18 ZA ZA2015/04408A patent/ZA201504408B/en unknown
-
2016
- 2016-03-22 HK HK16103299.4A patent/HK1215194A1/zh unknown
-
2019
- 2019-06-21 HR HRP20191137TT patent/HRP20191137T1/hr unknown
- 2019-06-27 CY CY20191100675T patent/CY1121895T1/el unknown
-
2020
- 2020-12-08 US US17/114,754 patent/US20210188964A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191137T1 (hr) | Formulacije otopina konstruiranih anti-il-23p19 antitijela | |
| HRP20191827T1 (hr) | Formulacija protutijela | |
| MX344727B (es) | Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. | |
| HRP20211371T1 (hr) | Stabilne, vodene formulacije protutijela | |
| NZ705178A (en) | Anti-prolactin receptor antibody formulations | |
| NZ627859A (en) | Stabilized formulations containing anti-ang2 antibodies | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| HRP20240159T1 (hr) | Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste | |
| SI2771031T1 (en) | Humanized antibodies that recognize alpha-synuclein | |
| RU2018119765A (ru) | Инъекционные препараты на основе ботулотоксина и способы их применения, обеспечивающие длительное терапевтическое и косметического действие | |
| PE20170780A1 (es) | Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf | |
| EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
| AR090272A1 (es) | FORMULACION DE ANTICUERPOS Ab | |
| PE20141413A1 (es) | Formulaciones de anticuerpo y metodos | |
| AR081042A1 (es) | Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g | |
| AR088671A1 (es) | Metodos para inhibir el crecimiento tumoral antagonizando el receptor de il-6 | |
| AR095496A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina | |
| JP2016505572A5 (hr) | ||
| PH12014502596A1 (en) | Pharmaceutical formulation | |
| HRP20181021T1 (hr) | Formulacija za bispecifične aktivatore limfocita t (bites) | |
| PE20191550A1 (es) | COMPOSICION FARMACEUTICA ACUOSA DE ANTICUERPO MONOCLONAL ANTI-TNFalfa RECOMBINANTE | |
| PE20220932A1 (es) | Composicion farmaceutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso | |
| CL2017001629A1 (es) | Formulaciones inyectables de paracetamol. | |
| MX2017000268A (es) | Administracion intradermica de una composicion de inmunoglobulina g. |